Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | January 26, 2026 | January 27, 2026 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director · President and CEO | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 217,779 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 37,313 · Balance 217,779 F1: All of the restricted stock will vest on January 26, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on January 26, 2027.
PRECISION BIOSCIENCES INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 573,888 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 573,888 · Balance 573,888 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:05 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 573,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040212 · wk-form4_1780517107.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,888 Underlying: Common Stock · 573,888 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 20,559 | $3.84 | $78,946.56 |
DisclosureSEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,392 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 67,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,593 Underlying: Common Stock · 67,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:31 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 67,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-009804 · wk-form4_1771536666.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003806 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,779 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| January 22, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 34,799 | $4.17 | $145,111.83 |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 4 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,154 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 69,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 7 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,421 Underlying: Common Stock · 69,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F7 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 37,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 6 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,069 Underlying: Common Stock · 37,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 8,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · derivative · entry 5 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 69,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 37,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 23:49 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 8,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-003149 · wk-form4_1769125738.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 9,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025. F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on November 2, 2025. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 3,409 | $6.49 | $22,124.41 |
DisclosureSEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,575 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| November 02, 2025 Filed Nov 4, 2025 21:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 9,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-048855 · wk-form4_1762290924.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 203,390 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081721 · ownership.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,390 Underlying: Common Stock · 203,390 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 22:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 964 | $5.56 | $5,359.84 |
DisclosureSEC source: 0000950170-25-044599 · ownership.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,540 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 22:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-044599 · ownership.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 21, 2025. F4 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 21, 2025. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 22:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 3,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-044599 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on March 21, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004750 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,466 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 36,838 | $4.67 | $172,033.46 |
DisclosureSEC source: 0000950170-25-008013 · ownership.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,087 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 69,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 5 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,842 Underlying: Common Stock · 69,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 37,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 4 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,138 Underlying: Common Stock · 37,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F5 · derivative.expiration_date: On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 8,888 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008013 · ownership.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 02:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 115,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-008013 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 00:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 3,012 | $8.19 | $24,668.28 |
DisclosureSEC source: 0000950170-24-121726 · ownership.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,537 F3 · kind: The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| November 02, 2024 Filed Nov 6, 2024 00:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 9,443 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-121726 · ownership.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,444 Underlying: Common Stock · 9,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 02, 2024 Filed Nov 6, 2024 00:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 9,443 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-121726 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on November 2, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 23:07 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-034052 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,365 F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d). F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 11:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 208,263 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-100019 · ownership.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,263 Underlying: Common Stock · 208,263 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 23,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026645 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,568 F1 · shares: All of the restricted stock will vest on July 8, 2025. Read SEC document |
| May 08, 2024 Filed May 9, 2024 00:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 8,334 | $12.00 | $100,008.00 |
DisclosureSEC source: 0000950170-24-056141 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,106 F1 · shares: Represents shares purchased through a definitive subscription agreement, pursuant to which the Issuer agreed to issue and sell shares of its common stock in a non-brokered private placement to certain members of its management. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:29 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 1,526 | $10.32 | $15,748.32 |
DisclosureSEC source: 0000950170-24-053112 · ownership.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,772 F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:29 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 3,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053112 · ownership.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,417 Underlying: Common Stock · 3,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F6 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:29 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 3,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-053112 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 21, 2024, and subsequent settlement of such vested RSUs on May 1, 2024. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 01:12 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 111,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046598 · ownership.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,217 Underlying: Common Stock · 111,217 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 00:17 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 137,390 | $0.36 | $49,460.40 |
DisclosureSEC source: 0001209191-24-002119 · doc4.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,433 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:17 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 266,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002119 · doc4.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 533,280 Underlying: Common Stock · 266,720 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 00:17 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 266,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002119 · doc4.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 493,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 22:07 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 125,025 | $0.40 | $50,010.00 |
DisclosureSEC source: 0001209191-23-054549 · doc4.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,103 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 22:07 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 283,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054549 · doc4.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 566,610 Underlying: Common Stock · 283,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F4 · derivative.exercise_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On November 2, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 22:07 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 283,390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054549 · doc4.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on November 2, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 5,508 | $3.91 | $21,542.34 |
DisclosureSEC source: 0001493152-23-034855 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,957 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 327 | $3.90 | $1,275.30 |
DisclosureSEC source: 0001493152-23-033446 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,465 F1 · kind: The transaction reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 338 | $4.45 | $1,504.10 |
DisclosureSEC source: 0001493152-23-021996 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,792 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 58,689 | $4.62 | $271,143.18 |
DisclosureSEC source: 0001493152-23-021653 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,130 F1 · shares: All of the restricted stock will vest on June 14, 2024. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 46,999 | $0.82 | $38,539.18 |
DisclosureSEC source: 0001209191-23-020716 · doc4.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,738 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 20:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 102,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-020716 · doc4.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,009 Underlying: Common Stock · 102,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 20:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 102,535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020716 · doc4.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 21, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 21:13 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 268 | $2.33 | $624.44 |
DisclosureSEC source: 0001493152-23-008429 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,441 F1 · acquired: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.